Background: Oral contraceptive is the most commonly used method of fertility control. Yasmin® is a combination of a novel progestogen with anti-androgenic and anti-mineralcorticoid activities (3 mg Drospirenone (DRSP) and 30μg ethinylestradiol (EE)). It has been shown in many clinical trials that Yasmin® is an efficacious oral contraceptive, lacking undesired effects as with other oral contraceptives such as weight gain. However, the effects of Yasmin® on sexual desire and libido have not been intensively investigated so far.
Objective: Investigate the effects of Yasmin® on sexual desire, libido and changes in the free androgen index (FAI) compare to Meliane® (75μg gestodene + 20μg ethinylestradiol).
Material and method: The authors’ report the results of a double blind randomized controlled study using a translated version of the Female Sexual Function Index questionnaire (FSFI) for the assessment of the sexual function. The free androgen index was calculated from measurements of testosterone and sexual hormone binding globulin.
Result: The result shows statistically significant improvements regarding sexual desire, arousal and overall satisfaction in the Yasmin® group. Additionally, an increased frequency of orgasms in the Meliane® group was reported. Statistically significant differences between the two treatments regarding changes in the FSFI score and changes in the free androgen index have not been observed.
Conclusion: The novel oral contraceptive containing drospirenone (Yasmin®) and the non-anti-androgenic progestin containing oral contraceptive (Meliane®) do not show unfavorable effects on sexual response and libido.

Keywords: Drospirenone, Sexual desire, Libido